MedTrace Logo

Botulinum Toxin Versus Active Strength Training in the Treatment of Lateral Epicondylitis

NCT00930709 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2014-12-31

No results posted yet for this study

Summary

The purpose of this study is to compare efficacy, feasibility and cost effectiveness of botulinum toxin type A injections to active nine weeks strength training and stretching program in the treatment of the chronic lateral epicondylitis.

The main hypothesis is that the botulinum toxin type A injections may enable more rapid pain relief while strength training may provide better functional results and less relapses during the follow-up.

Conditions

  • Epicondylitis, Lateral Humeral
  • Tennis Elbow

Interventions

DRUG

Botulinum toxin type A (Botox®, Allergan)

Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.

BEHAVIORAL

Active strength training and stretching

Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.

Sponsors & Collaborators

  • Seinajoki Central Hospital

    lead OTHER

Principal Investigators

  • Aki Vainionpää, M.D., Ph.D. · Department of Physical Medicine and Rehabilitation, Seinäjoki Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930709 on ClinicalTrials.gov